Beijing Biohealthcare Biotechnology Co.,Ltd   Report issue

For profit Phase 2
Founded: Beijing China (2012)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2014
NCT02504229
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 5